Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta-Analysis
International Archives of Allergy and Immunology · 2025
DOI: 10.1159/000548019 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift International Archives of Allergy and Immunology, 2025. Verfasst von Han-Ying Tian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Harbin Medical University, Harbin, China. Hauptthemen laut MEDLINE: Chronic Urticaria, Histamine H1 Antagonists, Non-Sedating. Die Arbeit nennt 68 Literaturangaben.
Abstract (Originalsprache)
Introduction
The latest international joint guideline supports the use of second-generation H1 antihistamines (sgAHs) as the first-line treatment for chronic spontaneous urticaria (CSU).
Methods
PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched for randomized controlled trials of various types of sgAHs in the treatment of CSU up to March 2025. For efficacy, the primary outcome was the change from baseline in the total symptom score, while the secondary outcomes were pruritus score and wheal score. For safety, the total numbers of all withdrawals due to adverse events and common adverse effects were extracted for each treatment, which included central nervous system side effects and anticholinergic side effects.
Results
We identified and included 24 randomized clinical trials (RCTs) involving 5,172 patients. Ebastine ranked first in the total symptom score (standardized mean difference [SMD)\ −2.80 [95% confidence interval (CI):−5.12 to −0.47]) and pruritus score (SMD −1.10 [95% CI: −2.06 to −0.13]), while olopatadine ranked first in the wheal score (SMD −0.84 [95% CI: −1.37 to −0.32]). Bepotastine besilate had a significantly lower incidence of somnolence in adverse events (odds ratio 0.15 [95% CI: 0.03–0.69]) than other sgAHs.
Conclusion
Both ebastine and olopatadine showed promising efficacy, and no significant differences were found in acceptability and safety compared with placebo. There are no meaningful differences in safety risks between different second-generation antihistamines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Harbin Medical University, Harbin, China.
- Department of Dermatology, Second Clinical College of Harbin Medical University, Heilongjiang, China.
- Department of Dermatology, Yinzhou District Second Hospital, Ningbo, China.
- Department of General Medicine, Anhui Medical University, Hefei, China.
- Department of Dermatology, Second Clinical College of Harbin Medical University, Heilongjiang, China, liyuzhen@hrbmu.edu.cn.
Zitieren
APA
Tian, H. Y., Xu, C., Liu, C. J., & Li, Y. Z. (2025). Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta-Analysis. International Archives of Allergy and Immunology. https://doi.org/10.1159/000548019
Vancouver
Tian HY, Xu C, Liu CJ, Li YZ. Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta-Analysis. International Archives of Allergy and Immunology. 2025. doi:10.1159/000548019
BibTeX
@article{Tian2025,
author = {Tian, Han-Ying and Xu, Chao and Liu, Cheng-Jiang and Li, Yu-Zhen},
title = {Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta-Analysis},
journal = {International Archives of Allergy and Immunology},
year = {2025},
doi = {10.1159/000548019}
}
EUVIMED